CD8A and neoplasm: In the ID8 model, animals receiving the same regimen showed prolonged survival, increased CD3+ and CD8+ TILs, increased neoantigen-specific CD8+ T-cell responses that were correlated with reduced tumor burden, and a systemic effect with elevated T helper (Th)1-polarizing plasma chemokines.